DISCO Pharmaceuticals and AbbVie Sign $2.5 Billion Cancer Drug Deal

DISCO Pharmaceuticals has entered into a strategic collaboration with AbbVie to discover and develop next-generation cancer treatments for solid tumors. The agreement focuses on developing AND-gated bispecific therapeutics designed to target cancer cells more precisely while reducing damage to healthy tissues.

Announced on November 19, 2026, the collaboration will combine DISCO’s proprietary DISCOtech surfaceome mapping platform with AbbVie’s global oncology research and development expertise.

Under the agreement, DISCO will receive $40 million in upfront payments and could earn up to $2.5 billion in additional option, development and other milestone payments. The company will also be eligible for tiered royalties on worldwide net sales of products developed through the collaboration.

As part of the partnership, DISCO will lead specific research activities to identify and develop potential drug candidates. Once these activities are completed, AbbVie will have the option to exclusively license selected programs and take them forward into further development.

The collaboration will focus on AND-gated bispecific therapeutics, an approach designed to recognize cancer cells by targeting two proteins present on their surface at the same time. Unlike treatments that target a single protein, this approach aims to improve the ability to distinguish cancer cells from healthy cells.

DISCO’s DISCOtech platform maps cell-surface proteins to identify combinations of targets that are more commonly found on cancer cells than on normal tissues. By using these target pairs, the company aims to develop antibody-drug conjugates (ADCs) and T-cell engagers with greater tumor selectivity.

The approach could help address one of the major challenges in cancer treatment: damaging healthy tissues while attacking tumors. Improving this selectivity may also help widen the therapeutic window and reduce unwanted side effects.

DISCO Pharmaceuticals is already advancing its internal pipeline of AND-gated therapies for difficult-to-treat cancers, with lead programs targeting small cell lung cancer and colorectal cancer progressing toward clinical development.

Mark Manfredi, Ph.D., CEO of DISCO Pharmaceuticals, said the collaboration with AbbVie represents an important opportunity to develop new precision medicines for patients with difficult-to-treat solid tumors. He highlighted the company’s platform as a way to identify tumor-selective target pairs and develop treatments that could offer improved safety.

Ajla Hrle, Ph.D., Chief Business Officer of DISCO Pharmaceuticals, added that the partnership supports the potential of the company’s technology and complements its existing internal and partnered pipeline programs.

The agreement adds to growing interest in bispecific cancer therapies, particularly approaches that aim to improve treatment precision in solid tumors. For DISCO, the partnership provides an opportunity to work with a major pharmaceutical company and potentially bring its next-generation cancer treatment candidates closer to patients.

For AbbVie, the collaboration expands its oncology research efforts and provides access to DISCO’s technology for discovering more selective cancer therapies.

You might also like